Meta-analysis of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin.

John Joseph Valentine McMurrayScott D SolomonJ Paul LockJoseph M MassaroFang ZhuWenjiong ZhouHicham SkaliEldrin F LewisMason W Freeman Yuan-Di C Halvorsen

Published in: Diabetes, obesity & metabolism (2023)

Bexagliflozin did not increase the risk of MACE in participants with T2D when compared with placebo or active control. Both the preapproval and postapproval thresholds for CV safety were met and bexagliflozin has been approved by the US Food and Drug Administration.

Keyphrases

drug administration
cardiovascular events
systematic review
coronary artery disease
cardiovascular disease
meta analyses
tyrosine kinase
double blind
human health
case control
randomized controlled trial
risk assessment
phase iii
open label
electronic health record